Sheniting

Sheniting is a branded pharmaceutical product marketed in China for the treatment of overactive bladder syndrome, a condition characterized by urinary urgency, frequency, and, in some patients, urge incontinence. Publicly available information associates Sheniting with Nanjing MeiRui Pharmaceuticals’ urology portfolio, later acquired by GSK, but does not disclose the precise active ingredient, molecular modality, or detailed mechanism of action; based on its indication, it is likely to act via modulation of bladder function (for example through neural or smooth-muscle pathways), consistent with standard pharmacologic approaches to overactive bladder, although its specific target and class have not been clearly described in accessible sources.[9]

Brand names

Sheniting